DK1071805T3 - Adenovirus vectors for disease treatment - Google Patents
Adenovirus vectors for disease treatmentInfo
- Publication number
- DK1071805T3 DK1071805T3 DK99918712.3T DK99918712T DK1071805T3 DK 1071805 T3 DK1071805 T3 DK 1071805T3 DK 99918712 T DK99918712 T DK 99918712T DK 1071805 T3 DK1071805 T3 DK 1071805T3
- Authority
- DK
- Denmark
- Prior art keywords
- gene
- adenoviral
- disease treatment
- adenovirus vectors
- expression
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
- C12Y305/04001—Cytosine deaminase (3.5.4.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Abstract
Adenoviral vectors, including mutant adenoviruses, that have restriction sites in the E3 region, that facilitate its partial or total deletion, or select genes contained therein, and compositions and methods for substituting heterologous gene(s), if desired, which gene(s) will exhibit an expression pattern, both in terms of timing and degree of expression, similar to the endogenous adenoviral gene that it replaces, and further optionally including mutations in other parts of the adenoviral genome, including certain E1B or E1A regions, and that have applications for diagnosing or treating disease, preferably disease involving unwanted cell growth, including cancer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8303398P | 1998-04-24 | 1998-04-24 | |
| US11710399P | 1999-01-25 | 1999-01-25 | |
| PCT/US1999/008656 WO1999055831A2 (en) | 1998-04-24 | 1999-04-19 | Adenoviral vectors for treating disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1071805T3 true DK1071805T3 (en) | 2011-09-26 |
Family
ID=26768867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK99918712.3T DK1071805T3 (en) | 1998-04-24 | 1999-04-19 | Adenovirus vectors for disease treatment |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1071805B1 (en) |
| JP (1) | JP2002512785A (en) |
| CN (1) | CN1298451A (en) |
| AT (1) | ATE517999T1 (en) |
| AU (1) | AU772963B2 (en) |
| CA (1) | CA2323235A1 (en) |
| CY (1) | CY1111931T1 (en) |
| DK (1) | DK1071805T3 (en) |
| PT (1) | PT1071805E (en) |
| WO (1) | WO1999055831A2 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1218527A2 (en) * | 1999-07-02 | 2002-07-03 | Onyx Pharmaceuticals, Inc. | Adenoviral vectors for treating disease |
| US6579522B1 (en) | 2000-06-27 | 2003-06-17 | Genvec, Inc. | Replication deficient adenoviral TNF vector |
| CA2439185A1 (en) | 2001-02-23 | 2002-09-06 | Novartis Ag | Vector constructs |
| US20030086903A1 (en) | 2001-11-02 | 2003-05-08 | Genvec, Inc. | Therapeutic regimen for treating cancer |
| CN100361710C (en) * | 2004-06-07 | 2008-01-16 | 成都康弘生物科技有限公司 | Construction and application of oncolytic adenovirus recombinant of tumor cell specifically expressing immunoregulation factor GM-CSF |
| CN1328372C (en) * | 2005-05-25 | 2007-07-25 | 上海希元生物技术有限公司 | Tumor target gene-virus ZD55-IL-24, construction method and application thereof |
| BR112012008060A2 (en) * | 2009-07-31 | 2016-11-22 | Paxvax Inc | adenovirus-based vectors |
| CN102174479B (en) * | 2011-03-02 | 2013-04-03 | 北京锤特生物科技有限公司 | Oncolytic virus for targeted treatment of human tumors and application thereof |
| US9404090B2 (en) | 2011-11-24 | 2016-08-02 | Viromed Co., Ltd. | Adenovirus producing novel cell line and the use thereof |
| WO2014153258A2 (en) * | 2013-03-14 | 2014-09-25 | Epeius Biotechnologies Corporation | Improved thymidine kinase gene |
| CA3064863A1 (en) * | 2017-05-26 | 2018-11-29 | Epicentrx, Inc. | Recombinant adenoviruses carrying transgenes |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585362A (en) * | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US6780406B1 (en) * | 1994-03-21 | 2004-08-24 | The Regents Of The University Of Michigan | Inhibition of vascular smooth muscle cell proliferation administering a thymidine kinase gene |
-
1999
- 1999-04-19 DK DK99918712.3T patent/DK1071805T3/en active
- 1999-04-19 EP EP99918712A patent/EP1071805B1/en not_active Expired - Lifetime
- 1999-04-19 AU AU36563/99A patent/AU772963B2/en not_active Ceased
- 1999-04-19 PT PT99918712T patent/PT1071805E/en unknown
- 1999-04-19 WO PCT/US1999/008656 patent/WO1999055831A2/en active IP Right Grant
- 1999-04-19 CA CA002323235A patent/CA2323235A1/en not_active Abandoned
- 1999-04-19 JP JP2000545977A patent/JP2002512785A/en active Pending
- 1999-04-19 AT AT99918712T patent/ATE517999T1/en active
- 1999-04-19 CN CN99805402A patent/CN1298451A/en active Pending
-
2011
- 2011-10-11 CY CY20111100974T patent/CY1111931T1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1298451A (en) | 2001-06-06 |
| EP1071805A2 (en) | 2001-01-31 |
| WO1999055831A2 (en) | 1999-11-04 |
| AU772963B2 (en) | 2004-05-13 |
| PT1071805E (en) | 2011-10-04 |
| JP2002512785A (en) | 2002-05-08 |
| WO1999055831A3 (en) | 2000-03-30 |
| ATE517999T1 (en) | 2011-08-15 |
| EP1071805B1 (en) | 2011-07-27 |
| CY1111931T1 (en) | 2015-11-04 |
| AU3656399A (en) | 1999-11-16 |
| CA2323235A1 (en) | 1999-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1111931T1 (en) | BODIES FOR DISEASE EDUCATION | |
| Nawroz et al. | Allelotype of head and neck squamous cell carcinoma | |
| WO1999035170A8 (en) | Compositions and methods for the treatment of tumor | |
| ATE213022T1 (en) | ADENOVIRAL VECTORS FOR GENE THERAPY | |
| EP0905253A3 (en) | Adenoviral vector deleted of all E4-ORF except ORF6 | |
| RU96112150A (en) | RECOMBINANT Adenovirus VECTOR AND WAYS OF ITS APPLICATION | |
| HUP0301318A2 (en) | Replication-defective recombinant adenovirus with mutated major late promoter | |
| DK1626058T3 (en) | Tumor diagnostic compositions and methods | |
| DK0797676T3 (en) | Recombinant adenoviral vector and methods for its use | |
| EP1657256A3 (en) | Compositions and methods for the treatment of tumor | |
| WO1999014327A3 (en) | Genes amplified in tumours, antibodies against the proteins coded thereby, and their use in diagnosis and treatment of cancer | |
| WO2003032813A3 (en) | Methods for the treatment of carcinoma | |
| JP2004536572A5 (en) | ||
| ATE488529T1 (en) | COMPOSITIONS AND METHODS FOR TREATING TUMORS | |
| WO2001002540A3 (en) | Adenoviral vectors for treating disease | |
| EP1100825A4 (en) | Human mink gene mutations associated with arrhythmia | |
| EP1642907A3 (en) | Composition and methods for the diagnosis of tumours | |
| Nomoto et al. | Structural basis for the regulation of UDP-N-acetyl-α-D-galactosamine: polypeptide N-acetylgalactosaminyl transferase-3 gene expression in adenocarcinoma cells | |
| WO2000015666A3 (en) | Compositions and methods for the treatment of tumors | |
| IL163745A (en) | Use of adenoviruses mutated in the va and vaii genes for the preparation of pharmaceutical compositions for cancer treatment | |
| Hussein et al. | Building bridges in cancer: mismatch repair and microsatellite instability | |
| Fogt et al. | Collecting duct carcinomas of the kidney: a comparative loss of heterozygosity study with clear cell renal cell carcinoma. | |
| WO2000022136A3 (en) | Recombinant e1a deleted adenoviral vectors | |
| UA70909C2 (en) | Recombinant adenovirus expression vector, pharmaceutical composition, and gene therapy aimed at inhibiting cancer cell proliferation | |
| DK1135514T3 (en) | E1b deleted adenoviral shuttle vectors |